CLINICAL STUDIES
Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease
Michael Shechter, MD, MA, FACC*   ,
C. Noel Bairey Merz, MD, FACC* ,
Maura J. Paul-Labrador, MPH* and
Sanjay Kaul, MD*
* Preventive and Rehabilitative Cardiac Center, Cedars-Sinai Burns and Allen Research Institute, Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
Atherosclerosis Research Center, Cedars-Sinai Burns and Allen Research Institute, Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
UCLA School of Medicine, Los Angeles, California, USA
Manuscript received July 27, 1998;
revised manuscript received August 16, 1999,
accepted October 18, 1999.
Reprint requests and correspondence: Dr. Sanjay Kaul, Division of Cardiology, Room 5314, Cedars-Sinai Medical Center, 8700, Beverly Boulevard, Los Angeles, California 90048
kaul{at}cshs.org
OBJECTIVES
To investigate the influence of blood glucose on platelet-dependent thrombosis (PDT).
BACKGROUND
Elevated blood glucose is a predictor of adverse cardiovascular risk independent of a diagnosis of diabetes, possibly due to adverse effects promoting thrombosis. The effects of blood glucose on PDT have not been characterized.
METHODS
An ex vivo extracorporeal perfusion protocol was used to measure PDT in 42 patients with stable coronary artery disease (CAD). The Badimon chamber was perfused with unanticoagulated venous blood and PDT evaluated using computerized morphometry. Whole blood impedance aggregometry and flow cytometry evaluated platelet aggregation and P-selectin expression, respectively.
RESULTS
Using a multivariate stepwise regression model, blood glucose was the best independent predictor of PDT (R2 = 0.19, p < 0.008), followed by apolipoprotein B (R2 = 0.18, p = 0.002) and intracellular magnesium levels (R2 = 0.12, p = 0.02). Platelet-dependent thrombosis was significantly greater in patients with blood glucose >, compared with  , the median value of 4.9 mmol/l (159 ± 141 vs. 67 ± 69 µm2/mm, p < 0.01). Neither platelet aggregation nor P-selectin expression was significantly different between the two groups. Insulin levels correlated with blood glucose (r = 0.56, p = 0.0003), but were not independently associated with either PDT, platelet aggregation or P-selectin expression. A two-way analysis of variance demonstrated an interaction between insulin (>126 pmol/l) and blood glucose (>4.9 mmol/l) in modulating PDT (F [1,38] = 8.5, p < 0.006).
CONCLUSIONS
Blood glucose is an independent predictor of PDT in stable CAD patients. The relationship is evident even in the range of blood glucose levels considered normal, indicating that the risk associated with blood glucose may be continuous and graded. These findings suggest that the increased CAD risk associated with elevated blood glucose may be, in part, related to enhanced platelet-mediated thrombogenesis.
|
Abbreviations and Acronyms
| | ADP | = adenosine diphosphate | | ANOVA | = analysis of variance | | BMI | = body mass index | | CAD | = coronary artery disease | | CHD | = coronary heart disease | | FBG | = fasting blood glucose | | HDL-C | = high-density lipoprotein cholesterol | | LDL-C | = low-density lipoprotein cholesterol | | NYHA | = New York Heart Association | | PDT | = platelet-dependent thrombosis |
|
This article has been cited by other articles:
|
|
|
|
 
K R Bainey, Y Fu, C B Granger, C W Hamm, D R Holmes Jr, W W O'Neill, R Seabra-Gomes, M E Pfisterer, F Van de Werf, P W Armstrong, et al.
Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients?
Heart,
August 15, 2009;
95(16):
1331 - 1336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Weston, L Walker, J Birkhead, and National Audit of Myocardial Infarction Project, N
Early impact of insulin treatment on mortality for hyperglycaemic patients without known diabetes who present with an acute coronary syndrome
Heart,
December 1, 2007;
93(12):
1542 - 1546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schafer, U. Flierl, A. Kobsar, M. Eigenthaler, G. Ertl, and J. Bauersachs
Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats
Arterioscler Thromb Vasc Biol,
December 1, 2006;
26(12):
2813 - 2818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Barsheshet, M. Garty, E. Grossman, A. Sandach, B. S. Lewis, S. Gottlieb, A. Shotan, S. Behar, A. Caspi, R. Schwartz, et al.
Admission Blood Glucose Level and Mortality Among Hospitalized Nondiabetic Patients With Heart Failure.
Arch Intern Med,
August 14, 2006;
166(15):
1613 - 1619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z Kadri, N Danchin, L Vaur, Y Cottin, P Gueret, M Zeller, J-M Lablanche, D Blanchard, G Hanania, N Genes, et al.
Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study
Heart,
July 1, 2006;
92(7):
910 - 915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schomig, C. Schmitt, A. Dibra, J. Mehilli, C. Volmer, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F.-J. Neumann, et al.
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel
Eur. Heart J.,
July 2, 2005;
26(14):
1379 - 1384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Aguilar, S. D. Solomon, L. Kober, J.-L. Rouleau, H. Skali, J. J.V. McMurray, G. S. Francis, M. Henis, C. M. O'Connor, R. Diaz, et al.
Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Circulation,
September 21, 2004;
110(12):
1572 - 1578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schafer, N. J. Alp, S. Cai, C. A. Lygate, S. Neubauer, M. Eigenthaler, J. Bauersachs, and K. M. Channon
Reduced Vascular NO Bioavailability in Diabetes Increases Platelet Activation In Vivo
Arterioscler Thromb Vasc Biol,
September 1, 2004;
24(9):
1720 - 1726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mudaliar
Intense Management of Diabetes Mellitus: Role of Glucose Control and Antiplatelet Agents
J. Clin. Pharmacol.,
April 1, 2004;
44(4):
414 - 422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Hurst and R. W. Lee
Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management
Ann Intern Med,
November 18, 2003;
139(10):
824 - 834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Koyama, T. Maeno, S. Fukumoto, T. Shoji, T. Yamane, H. Yokoyama, M. Emoto, T. Shoji, H. Tahara, M. Inaba, et al.
Platelet P-Selectin Expression Is Associated With Atherosclerotic Wall Thickness in Carotid Artery in Humans
Circulation,
August 5, 2003;
108(5):
524 - 529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Iwakura, H. Ito, M. Ikushima, S. Kawano, A. Okamura, K. Asano, T. Kuroda, K. Tanaka, T. Masuyama, M. Hori, et al.
Association between hyperglycemia and the no-reflow phenomenon inpatients with acute myocardial infarction
J. Am. Coll. Cardiol.,
January 1, 2003;
41(1):
1 - 7.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P Marso
Review: The pathogenesis of type 2 diabetes and cardiovascular disease
The British Journal of Diabetes & Vascular Disease,
September 1, 2002;
2(5):
350 - 356.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. S. Sabatine and E. Braunwald
Will Diabetes Save the Platelet Blockers?
Circulation,
December 4, 2001;
104(23):
2759 - 2761.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kennon, K. Barakat, G. A. Hitman, C. P. Price, P. G. Mills, K. Ranjadayalan, J. Cooper, H. Clark, and A. D. Timmis
Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes
J. Am. Coll. Cardiol.,
September 1, 2001;
38(3):
724 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Vinik, T. Erbas, T. S. Park, R. Nolan, and G. L. Pittenger
Platelet Dysfunction in Type 2 Diabetes
Diabetes Care,
August 1, 2001;
24(8):
1476 - 1485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
